Report LibraryAll Reports
Datamonitor Healthcare CV&Met Disease Analysis: Anemia in Chronic Kidney Disease
November 20, 2020The anemia in chronic kidney disease (CKD) market has struggled as usage of high-selling, standard-of-care, injectable erythropoiesis- stimulating agents (ESAs) has declined, especially in the US, due to an increased risk of cardiovascular events when targeting higher Hb levels, which has led to lower Hb targets and more caution when deciding to initiate the drugs. Biosimilars have also taken their toll, particularly in Europe, where biosimilar short-acting ESAs have taken a majority share of usage. The first biosimilar in the US, Retacrit, was only approved in 2018, so is still ramping. The ESAs are poised to lose substantial further share and possibly be eventually displaced by the oral and potentially safer HIF-PH inhibitors, with roxadustat on track for initial approval in the important US market in late 2020, having already been approved in Japan and China. It will be important to see, though, more details from its FDA review. The HIF-PH inhibitors also reduce the dose of IV iron needed in dialysis patients, and appear to have other advantages as well.
This Datamonitor Healthcare report contains a Disease Analysis module.
Anemia Due to Chronic Renal Failure, Dialysis-Dependent
Anemia Due to Chronic Renal Failure, Dialysis-Independent
Renal Disease / Renal Failure